Race Oncology Advanced Phase One Cardioprotection, Anti-Cancer Drug Candidate Clinical Trial in the September Quarter

MT Newswires Live

Oct 31

Race Oncology (ASX:RAC) said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.

It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.

It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.

Its shares fell 2% in recent trading on Friday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579848629"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579848629\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579848629?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579848629","market":"nz","top_or_hot":-1,"title":"Race Oncology Advanced Phase One Cardioprotection, Anti-Cancer Drug Candidate Clinical Trial in the September Quarter","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RAC.AU\">Race Oncology</a> (ASX:RAC) said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.</p><p>It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.</p><p>It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.</p><p>Its shares fell 2% in recent trading on Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Race Oncology Advanced Phase One Cardioprotection, Anti-Cancer Drug Candidate Clinical Trial in the September Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRace Oncology Advanced Phase One Cardioprotection, Anti-Cancer Drug Candidate Clinical Trial in the September Quarter\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-31 09:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RAC.AU\">Race Oncology</a> (ASX:RAC) said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.</p><p>It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.</p><p>It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.</p><p>Its shares fell 2% in recent trading on Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RAC.AU","symbol_name":"RACE ONCOLOGY LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2579848629","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579848629","pubTimestamp":1761875382,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Race Oncology  said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.Its shares fell 2% in recent trading on Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RAC.AU":"RACE ONCOLOGY LTD","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Race Oncology高级一期心脏保护、抗癌候选药物临床试验将于9月季度进行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAC.AU":1},"content_text":"Race Oncology (ASX:RAC) said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.Its shares fell 2% in recent trading on Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}